Previously untreated AML receiving TAG-AZA-VEN, subgroup survival outcomes. (A) OS probability in the previously untreated AML TAG-AZA-VEN cohort, separated by TP53 mutant (n = 13, TP53 mut, blue) or TP53 wild-type (n = 13, TP53 WT, red). (B) PFS probability for the TP53 subgroups as in panel A. (C) OS probability for patients in the previously untreated AML TAG-AZA-VEN cohort that achieved CR/CRi/MLFS, separated by those determined to be MRD negative (n = 12, MRD neg, red) or positive (n = 5, MRD pos, blue). (D) PFS probability for the MRD subgroups as in panel C. (E) OS probability in the previously untreated AML TAG-AZA-VEN cohort, separated by those who received allogeneic stem cell transplant (n = 13, alloSCT Y, red) or those who did not (n = 13, alloSCT N, blue). (F) PFS probability for the alloSCT subgroups as in panel E. alloSCT, allogeneic stem cell transplantation.